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Abstract: Massive transfusion protocols (MTPs) are established to provide rapid blood 
replacement in a setting of severe hemorrhage. Early optimal blood transfusion is essential to 
sustain organ perfusion and oxygenation. There are many variables to consider when establishing 
an MTP, and studies have prospectively evaluated different scenarios and patient populations 
to establish the best practices to attain improved patient outcomes. The establishment and 
utilization of an optimal MTP is challenging given the ever-changing patient status during 
resuscitation efforts. Much of the MTP literature comes from the trauma population, due to 
the fact that massive hemorrhage is the leading cause of preventable trauma-related death. As 
we come to further understand the positive and negative clinical impacts of transfusion-related 
factors, massive transfusion practice can be further reﬁned. This article will ﬁrst discuss speciﬁc 
MTPs targeting different patient populations and current relevant international guidelines. Then, 
we will examine a wide selection of therapeutic products to support MTPs, including newly 
available products and the most suitable of the traditional products. Lastly, we will discuss the 
best design for an MTP, including ratio-based MTPs and MTPs based on the use of point-of-
care coagulation diagnostic tools.
Keywords: hemorrhage, MTP, antiﬁbrinolytics, coagulopathy, trauma, ratio, logistics, guidelines, 
hemostatic
Introduction and definition of massive transfusion
The importance of prompt blood replacement in the setting of uncontrolled hemorrhage 
is well established and intuitively practiced to resuscitate exsanguinating patients. 
During combat, trauma-associated hemorrhage due to penetrating or blunt injury is often 
supported by transfusion of whole blood (WB) collected directly from other soldiers. 
This historical military practice has evolved into a bleeding management strategy for 
hemorrhagic shock known as damage control resuscitation in the civilian setting. While 
the military massive transfusion (MT) practices have been reﬁned to improve outcomes 
over time, the difference in the types of traumatic or non-traumatic injuries, patient 
health conditions, availability of blood products, and provider-related factors must be 
considered before applying the same MT practices to a civilian setting.1,2 The objective 
of this article is to provide guidance on how to optimize massive transfusion protocols 
(MTPs) in the trauma and non-trauma settings. We will deﬁne MT and discuss different 
types of MTPs, review expert guidelines available for MTPs, provide guidance for the 
use of therapeutic hemostatic products, discuss the relevance of point-of-care (POC) 
coagulation testing and blood product ratios during an MTP, and ﬁnally conclude with 
practical logistical and safety considerations maximize an MTP.
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Definition of MT
MT is deﬁned when either 1) total blood volume is replaced 
within 24 hours, 2) 50% of total blood volume is replaced 
within 3 hours, or 3) rapid bleeding rate is documented or 
observed. Rapid bleeding rate in adults can be deﬁned as 
more than 4 units of red blood cells (RBCs) transfused 
within 4 hours with active major bleeding or more than 
150 mL/minute of blood loss. The deﬁnition of MT in 
children is slightly different from the deﬁnition in adults but 
is beyond the scope of this review.3,4
Types of MTPs
Trauma MTPs
At the onset of severe traumatic bleeding, aggressive 
ﬂuid replacement and rapid mechanical/surgical bleeding 
control can often mitigate the extent of tissue injury, 
inﬂammation, and hypoperfusion. However, untimely 
or incomplete control of massive bleeding can lead to 
systemic consumptive coagulopathy with hemodilution 
and endothelial damage.5,6 If the systemic damage remains 
uncorrected, concurrent trauma-associated hypothermia 
and acidosis can further exacerbate coagulopathy and lead 
to irreversible  multiorgan failure (MOF). In addition, older 
age (55 years old), high injury severity score (ISS15), 
high base deﬁcit (8 mEq/L), high lactate (2.5 mmol/L), 
and blood transfusion have been observed as independent 
risk factors for MOF in both retrospective and prospec-
tive studies.7,8 Catastrophic exsanguination is the second 
leading cause of death during traumatic injury; thus, the 
resuscitative goal of MT includes rapid hemostasis and 
maintenance of adequate tissue oxygenation to prevent 
end organ damage. Various MT algorithms have been 
published and depend on a hospital’s capabilities and 
preferences (Table 1).
Non-trauma MTPs
Refractory bleeding due to medical illness or surgical 
procedures often requires signiﬁcant ﬂuid replacement, 
including blood product transfusion, to resuscitate patients. 
Various clinical settings, such as gastrointestinal bleeding, 
intracranial bleeding, vascular surgical bleeding, and general 
surgical bleeding, are common indications for non-trauma 
MTPs when massive hemorrhage deﬁnitions are met. Many 
times trauma MTP algorithms are usually adopted fully 
or with minimal modiﬁcations in the non-trauma setting 
given the ease of transferring this practice. However, the 
optimal algorithm has not been impartially established or 
prospectively validated. A retrospective study showed that 
the use of an MTP in a non-trauma setting was associated 
with poor clinical outcomes, most probably related to 
underlying disease, not the MTP itself.9,10 However, this 
study and a similar retrospective study10 both observed 
that non-trauma MTPs were over-activated more than 50% 
of the time without subsequent MT. In one of the studies 
examining blood product wastage, platelet wastage was 
signiﬁcantly higher in non-trauma MTPs versus trauma 
MTPs (12.8% versus 8.1%).10 Prospective studies are clearly 
needed to optimize non-trauma MTPs, including validation 
of different ratios and development of screening/prediction 
tools to determine which patients would most beneﬁt from 
an MTP.
Current MT guidelines
Guidelines are designed to provide evidence-based, well-
balanced information regarding the beneﬁts and limitations 
of therapeutic interventions. Two major guidelines are 
available for MT: the European guidelines by the Task 
Force for Advanced Bleeding Care in Trauma (updated 
in 2013) and the Trauma Quality Improvement Program 
(TQIP) recommendations from the American College of 
Surgeons.11 The Task Force has included a new dedicated 
section discussing the implementation and adherence to 
evidence-based, protocolized clinical practices relating to 
blood transfusion in bleeding trauma patients. Notably, 
a signiﬁcant portion of these guidelines is dedicated to a 
discussion of the utility of rapid and pertinent laboratory 
tests, evaluation of clinically signiﬁcant hemorrhage, and 
administration of appropriate blood products for resuscitation 
in a timely manner. Similarly, the 2011 update on the clinical 
practice guidelines for blood conservation from the Society 
of Thoracic Surgeons and the Society of Cardiovascular 
Anesthesiologists also advocates the judicious use of blood 
products, factor concentrates, hemostatic agents, and blood 
salvage to minimize blood loss.12 In addition, the American 
College of Surgeons has established the TQIP to provide 
recommendations for the care provided to trauma patients. 
It also provides guidelines for MTPs, which emphasize tight 
collaboration among blood banks, emergency departments, 
anesthesiologists, and trauma services. TQIP recommends 
that an MTP needs to deﬁne protocol triggers for activation/
deactivation, an algorithm for preparation and delivery of 
blood products, including continued support in the non-
emergency department (ED) setting. The guidelines advocate 
the establishment of transfusion targets, recommend the use 
of pharmacologic hemostatic agents, and suggest ongoing 
evaluation of cumulative MTP performance. A recent survey 
by TQIP evaluated over 180 registered trauma centers on their 
current MTP practices (Table 2).13
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Selection of available blood 
products
Red blood cells
To minimize blood product wastage, most blood banks 
aim to transfuse the oldest units ﬁrst. However, the clinical 
impact of the RBC storage lesion has been heavily discussed 
and debated recently.14 The clinical effect of storage lesions 
and transfusing older RBCs has been insightfully described 
by Wang et al in a meta-analysis article evaluating over 
20 published studies, which suggested that transfusing older 
blood is signiﬁcantly associated with an increased mortality 
risk. However, the signiﬁcance of this association appears 
Table 1 Published patient-cohort specific massive transfusion protocols
Source (year) Package 1 Package 2 Package 3 Note
Adult MTP
O’Keeffe et al85 (2008) 5 RBCs, 2 AB TP 5 RBCs, 2 TP, 1 SDP 5 RBCs, 2 TP, 10U  
cryo, FVIIa
Cotton et al86 (2009) 10 RBCs, 4 AB TP, 2 SDP 6 RBCs, 4 AB TP, 2 SDP Repeat package 2 Cryo with physician request
Dente et al87 (2009) 6 RBCs, 4 AB TP 6 RBCs, 6 TP, 1 SDP 6 RBCs, 6 TP, 10U cryo rFVIIa at clinician discretion
Riskin et al88 (2009) 6 RBCs, 4 FFP, 1 SDP Repeat package 1 Repeat package 1 Consider rFVIIa after 2 rounds
Nunez et al89 (2010) 10 RBCs, 6 AB TP, 2 SDP Repeat package 1 Repeat package 1
Tan et al90 (2012) 4 RBC, 4 AB FFP 4 RBC, 4 AB FFP 4 RBC, 4 AB FFP, 2 SDP rFVIIa is considered for 
refractory bleeding and is at 
trauma team’s discretion
Ball et al91 (2013) 6 RBCs, 6 plasma 6 RBCs, 6 plasma, 1 SDP 6 RBCs, 6 plasma,  
20U cryo
Consider rFVIIa after 2 rounds 
(abdominal surgery)
Bawazeer et al92 (2015) 6 RBCs, 4 AB FFP, 1 SDP 4 RBCs, 4 FFP Repeat package 2 10U cryo when fibrinogen 
1.5 g/L, and rFVIIa is at 
physician’s discretion
Maciel et al93 (2015) 6 RBCs, 4 FFP, 1 SDP RBC:FFP (1:1) plus cryo  
and SDP
Repeat package 2 rVIIa and TXA are at 
physician’s discretion 
(abdominal aoritic injury)
Pediatric/adolescent MTP
Riskin et al88 (2009) 4 RBCs, 2 FFP, 1 SDP Repeat package 1 Repeat package 1 Consider rFVIIa after 2 rounds
Dressler et al94 (2010) 1 RBC, 1 plasma, 1 RDP Repeat package 1 Repeat package 1 3 kg, rFVIIa and cryo are  
at physician’s discretion
2 RBC, 2 plasma, 2 RDP Repeat package 1 Repeat package 1 3–20 kg, rFVIIa and cryo are  
at physician’s discretion
4 RBC, 4 plasma, 4 RDP Repeat package 1 Repeat package 1 21–40 kg, rFVIIa and cryo  
are at physician’s discretion
6 RBC, 6 plasma, 6 RDP Repeat package 1 Repeat package 1 40 kg, rFVIIa and cryo are  
at physician’s discretion
Pickett and Tripi95 (2011) 6 RBC, 3 FFP, 5 RDP 5 RBC, 3 FFP, 5 RDP 5 RBC, 2 FFP, 5 RDP,  
10U cryo
Chidester et al96 (2012) 1 RBC, 1 FFP, 1 RDP Repeat package 1 Repeat package 1 rFVIIa is at physician’s 
discretion
Hendrickson et al97 (2012) 1/2 RBC, 1/2 plasma 1/2 RBC, 1/2 plasma, 1/2 
SDP
1/2 RBC, 1/2 plasma, 1 
U cryo
Neonate (1–5 kg), 1 dose of 
rFVIIa at physician’s discretion
1 RBC, 1 plasma 1 RBC, 1 plasma, 1/2 SDP 1 RBC, 1 plasma, 2U cryo Infant (6–10 kg), 1 dose of 
rFVIIa at physician’s discretion
2 RBC, 2 plasma 2 RBC, 2 plasma, 1 SDP 2 RBC, 2 plasma, 4U cryo Younger child (11–25 kg),  
1 dose of rFVIIa at physician’s 
discretion
3 RBC, 3 plasma 3 RBC, 3 plasma, 1 SDP 3 RBC, 3 plasma, 6U Cryo older child (26–50 kg),  
1 dose of rFVIIa at physician’s 
discretion
5 RBC, 5 plasma 5 RBC, 5 plasma, 1 SDP 5 RBC, 5 plasma, 8U cryo 
adolescent
50 kg, 1 dose of rFVIIa at 
physician’s discretion
Obstetric MTP
Gutierrez et al98 (2012) 6 RBCs, 4 AB TP or LP, 1 
SDP
Repeat package 1 Repeat package 1 Consider rFVIIa as salvage 
treatment
Note: 1U cryo 1 individual unit (not 5- or 10-pooled unit) of cryoprecipitate.
Abbreviations: RBCs, red blood cells; RDP, random donor platelets; SDP, single donor apheresis platelets; FFP, fresh frozen plasma; TP, thawed plasma; LP, liquid plasma; 
TXA, tranexamic acid; rFVIIa, recombinant-activated factor VII.

,Q
WH
UQ
DW
LR
QD
O-
RX
UQ
DO
R
I&
OLQ
LF
DO
7
UD
QV
IX
VL
RQ
0
HG
LF
LQ
H
GR
Z
QO
RD
GH
G
IUR
P
K
WWS
V
Z
Z
Z
G
RY
HS
UH
VV
F
RP
E
\






R
Q

6
HS



)R
US
HU
VR
QD
OX
VH
R
QO
\
International Journal of Clinical Transfusion Medicine 2016:4submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
18
Hsu et al
to vary with different patient populations.15 McDaniel et al 
found that the age of RBCs transfused during non-trauma 
MTPs was not signiﬁcantly different from during trauma 
MTPs. However, the age of transfused RBCs increased signif-
icantly when the patient was switched to type-speciﬁc RBCs, 
which inevitably happens during MTPs.16 This is commonly 
practiced in many hospitals in order to preserve the Group 
O RhesusD (RhD) negative RBC inventory. In addition, the 
age of uncrossmatched Group O RBCs reserved for MTPs 
will vary due to hospital-speciﬁc RBC product management, 
thus further studies are needed in this area. Prospective 
randomized controlled trials (RCTs), including the ARIPI, 
ABLE, and RECESS trials, have shown that fresher RBCs 
do not signiﬁcantly improve clinical outcomes or mortality in 
various clinical settings.17–19 However, no prospective clinical 
trial has been published on the effect of RBC storage age on 
outcomes for MT patients.
Immune-mediated hemolysis is another clinical concern 
during the MTP. Due to the emergent need for blood prod-
ucts, routine pre-transfusion testing is bypassed and uncross-
matched Group O RhD negative RBCs are often given. This 
removal of safety assurances received from the antibody 
screen and product cross-matching leaves alloimmunized 
patients at increased risk for acute or delayed hemolysis.20 
In addition, residual plasma within Group O RBC units can 
accumulate when large quantities of Group O RBC units are 
transfused. This may theoretically lead to hemolysis due to 
ABO incompatibility based on retrospective evidence gar-
nered from transfusing out-of-group platelets with minor 
ABO group incompatibility.21,22 Thus, for A, B, or AB 
patients, it is safest to repeat the blood type, with particular 
consideration of the reverse type, before resuming transfusion 
of RBCs of the patient’s own blood group.
Plasma
Circulating coagulation factors have variable half-lives and 
are homeostatically maintained. During massive hemorrhage, 
the acute nature of signiﬁcant blood volume loss could lead to 
uncompensated coagulopathy. Therefore, early transfusion of 
plasma-containing physiologic coagulation factors intuitively 
should reverse this condition. Until recently, universal Group 
AB plasma has been the standard product used during MT 
when the patient’s blood group is initially unknown. Since 
Group AB donors comprise only approximately 4% of all 
eligible US blood donors, and the availability of Group AB 
plasma donors has been further reduced by the transfusion-
 related acute lung injury (TRALI) mitigation strategies, Group 
AB plasma and platelet products remain scarce resources. 
To resolve this dilemma, the use of Group A plasma with 
low titer anti-B agglutinin has been considered as a practi-
cal alternative to Group AB plasma. Group A US donors are 
approximately ten times more abundant than AB donors.23 
Zielinski et al evaluated the clinical impact of using universal 
untitered Group A plasma transfusion and found that approxi-
mately 14% of study subjects received incompatible plasma 
but no signiﬁcant adverse events occurred. Notably, this 
practice reduced the use of AB plasma by more than 95%.24 
Another retrospective study by Chhibber et al examined the 
outcomes associated with the use of Group A plasma versus 
Group AB plasma in an emergency setting. Of the 23 patients 
with blood Group B or AB, no hemolytic or other adverse 
reactions were detected.25 Thus, transfusing low-titer A or 
even untested Group A plasma is a practical approach in 
MT practice.26 On the contrary, neither low-titer Group A or 
untitered Group A plasma is considered equivalent to Group 
AB plasma during routine plasma transfusion practice.
There are multiple plasma products available in the blood 
bank (Table 3). The selection of the product is determined 
by timeliness of product availability and the coagulation 
factor content. Thawing large amounts of frozen plasma 
during an MTP presents a formidable logistical challenge 
to deliver the plasma products within 5–10 minutes of the 
Table 2 Summary of 2013 American College of Surgeons Trauma 
Quality Improvement Program (ACS-TQIP) Survey
Surveyed categories Major findings (% of surveyed  
ACS-TQIP trauma centers)
Prehospital resuscitation The most common blood products used  
were RBCs (28%) and plasma (10%)
The most common intravenous  
hemostatic agent used is TXA (15%)
MTP activation triggers The most common trigger used was  
hypotension (56%), defined as SBP  
of 100 mmHg (86%)
Laboratory values were used  
infrequently (26%) to initiate MTP
Blood product use  
and policies
Plasma is available immediately or in  
5 minutes (64%–72%). The most common  
plasma type used was thawed plasma or  
plasma frozen within 24 hours (78%)
The most common plasma:RBC ratio  
in the first cooler was 1:2 (88%)
The platelet:RBC ratio of 1:2 in the  
first blood pack was targeted (79%)
The use of cryoprecipitate was  
integrated in the MTP policies (49%)
Hemostatic agent  
(at hospital)
The most common intravenous hemostatic  
agent used was TXA (50%)
Point of care  
coagulopathy evaluation
The integration of TEG in the MTP policies  
was low (18%)
Abbreviations: RBCs, red blood cells; TEG, thrombelastography; MTP, massive 
transfusion protocol; TXA, tranexamic acid; SBP, systolic blood pressure.
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request. In the US after fresh frozen plasma or plasma frozen 
within 24 hours is thawed and stored for 24 hours, it can be 
relabeled as thawed plasma (TP) with up to ﬁve more days of 
shelf life. Therefore, TP has gained wide acceptance for MTP 
use. An observational study evaluating the implementation 
of TP in an emergency transfusion protocol demonstrated a 
signiﬁcant reduction for plasma delivery time, overall blood 
transfusion volume, and 24-hour and 30-day mortality.27 TP 
has relatively less factor V and factor VIII than fresh frozen 
plasma and plasma frozen within 24 hours. Liquid plasma 
(LP) is plasma recovered within 5 days of expiration from 
a WB product (never frozen); therefore, it has a shelf life 
of 26 days from the day of collection. In vitro studies have 
shown that LP, when stored at 1oC–6oC for up to 26 days, 
appears to provide similar hemostatic properties to TP as 
assessed by thrombelastography (TEG) and inhibition of 
vascular endothelial cell permeability by the endothelial 
monolayer assay.28 Goodnough et al reported that Group 
AB LP may be an acceptable alternative plasma product for 
trauma patients with unknown blood groups.29 In comparison 
to traditional plasma products, lyophilized plasma is logisti-
cally more convenient to use during an emergency situation. 
In Germany, LyoPlas N is a single donor-derived product 
that can be stored at room temperature up to 15 months and 
is transfusion-related acute lung injury mitigation strategy 
compliant. While the single donor source reduces the risk of 
infection compared to pooled products, the product requires 
blood type-speciﬁc transfusion. A counterpart in France 
is branded INTERCEPT Lyoplasma. In contrast, this is a 
pooled, leukoreduced, pathogen-inactivated plasma product 
pooled from up to eleven donors. Lyoplasma can be stored 
at room temperature for up to 2 years and can be adminis-
tered without ABO restriction. While these products are not 
yet clinically available worldwide, they are currently being 
evaluated in clinical trials.
Platelets
After collection from blood donors, platelets are typically 
stored between 20oC and 24oC with constant agitation for 
up to 5 days. In vitro and animal model-based studies have 
shown that refrigerated platelets have a shortened half-life 
in circulation.30,31 While refrigeration (1oC–6oC) is associ-
ated with decreased platelet viability and post-infusion 
increments, cold platelets have been shown to more readily 
aggregate in vitro and to have a better metabolic proﬁle.32,33 
During emergency resuscitation, the clinical emphasis often 
weighs more in favor of achieving rapid hemostasis rather 
than a durable increase in platelet count. Therefore, it has 
been suggested that refrigerated platelets dedicated for 
emergency transfusion may have clinical beneﬁts.
Whole blood
In MT, blood component therapy attempts to recapitulate 
the qualities of WB; thus, the direct use of WB for bleeding 
trauma patients in a civilian setting has gained increasing 
attention. A platelet-sparing leukoreduction ﬁlter (ImuFlex, 
Terumo BCT, Lakewood, CO) system was recently approved 
by the FDA for WB processing. A single institution RCT 
evaluated the 24-hour transfusion volume in trauma patients 
receiving either WB or blood component therapy. While 
WB transfusion did not signiﬁcantly reduce the transfu-
sion volume in all patients, a portion of the trauma patients 
transfused with WB did receive signiﬁcantly less blood 
volume.34 There are ongoing clinical trials to examine the 
effects of WB transfusion in emergency settings. The major 
hurdle preventing the widespread use of platelet-sparing 
WB products is the lack of consensus on the optimal stor-
age condition. An in vitro functional analysis on stored 
pathogen-inactivated WB treated with riboflavin and 
ultraviolet light revealed that a colder storage temperature 
(4oC) signiﬁcantly preserved the hemostatic properties and 
Table 3 Emergency plasma products available for massive transfusion
Plasma type Clinical use (country) Thawing time Donor exposure Universal use? Product expiration 
USA (hours)
Fresh frozen plasma  
(thawed)
Worldwide 30–45 minutes 1 No 24 at 1oC–6oC
Thawed plasma USA No modification 1 No 120 at 1oC–6oC
Liquid plasma USA No modification 1 No 624 at 1oC–6oC
Lyophilized plasma
LyoPlasN® Germany Bedside reconstitution 1 No Immediate use
INTERCEPT Lyoplasma® France Bedside reconstitution 11 Yes Immediate use
Pathogen-inactivated plasma
Amotosalen (Intercept®) Multiple 30–45 minutes 1 No 24 at 1oC–6oC
Solvent detergent (Octaplas®) Multiple 30–45 minutes 1,000–1,500 No 24 at 1oC–6oC
8 at 20oC–25oC
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platelet function.35 Another major limitation to the use of 
WB is the requirement for type-speciﬁc blood, as the patient 
blood type is frequently unknown during the early phase 
of resuscitation. Although WB appears to be a promising 
practice during MT, more practice optimization is needed 
prior to its wide acceptance.
Hemostatic therapies
The use of lyophilized factor concentrates and pharmacologic 
agents during MT has gained popularity as they can be stored 
and administered at the bedside to avoid time delays due to 
product processing and issuing. In addition, this allows the 
use of target-speciﬁc treatment rather than the broad and 
non-speciﬁc use of plasma to attempt to correct all coagul-
opathies. Three factor concentrates have been used in MT: 
prothrombin complex concentrates (PCCs), recombinant-
activated factor VII, and ﬁbrinogen concentrate.
Recombinant-activated factor VII  
(rFVIIa) and PCCs
Two main coagulation events determine the success of 
rapid and sustained clot formation: thrombin generation 
and ﬁbrin formation. With rapid activation of thrombin in 
the presence of adequate ﬁbrinogen and platelets, the early 
use of rFVIIa was associated with less blood product usage 
and lower mortality in military patients requiring MT.36–38 
A recent meta-analysis on the use of rFVIIa, in both military 
and civilian populations, for the prevention and treatment of 
hemorrhage demonstrated favorable trends in reducing blood 
product usage and mortality; however, there is a concurrent 
trend of increased thromboembolic adverse outcomes with 
rFVIIa.39 Therefore, rFVIIa is not recommended for routine 
use during MT practices.
The use of 3- or 4-factor PCCs in a MT setting is observed 
due to its rapid availability and potent/rapid restoration of key 
vitamin K-dependent clotting factors in a concentrated, low 
volume dose. PCCs are not available or approved for use in 
a MT setting in all countries. However, the use of PCCs in 
dilutional coagulopathy and other clinical settings has been 
published to show signiﬁcant hemostatic efﬁcacy. In parallel, 
PCCs may carry potential enhanced risk of thrombosis in 
subsets of MT patients due to patients’ increased circulating 
tissue factor and decreased plasma or endothelial anticoagu-
lant activity.40 With the lack of safety evidence, European 
guidelines do not endorse the use of PCC in a MT setting.11 
Collectively, these hemostatic agents are potent drugs with a 
risk of thrombosis; therefore, the risk-to-beneﬁt ratio should 
be carefully considered in an MT setting.
Fibrinogen concentrate
Fibrinogen is a coagulation factor with a large molecular 
weight and a long half-life. When signiﬁcant intravascular loss 
due to prolonged bleeding occurs, its recovery will be delayed 
and can rapidly become clinically signiﬁcant.41 Worldwide, 
cryoprecipitate remains the most common blood product used 
to replace ﬁbrinogen and contains approximately 200–250 mg 
of ﬁbrinogen per unit. In addition to the time delay from thaw-
ing the cryoprecipitate, the thawed product expires within 6 
hours in most countries. This leads to delayed availability and 
increased product wastage. Furthermore, cryoprecipitate is a 
pooled product, but not pathogen inactivated. While ﬁbrinogen 
concentrate was originally developed and approved to treat 
congenital aﬁbrinogenemia, many in vitro and animal models 
have shown that ﬁbrinogen concentrate can strengthen clot 
ﬁrmness and achieve early hemostasis in the presence of throm-
bocytopenia and dilutional coagulopathy.42,43 A retrospective 
study correlating the ﬁbrinogen level with mortality in criti-
cally injured patients revealed that ﬁbrinogen levels less than 
180 mg dL1 were signiﬁcantly associated with higher in-hos-
pital death.44 Fibrinogen replacement has been shown to hasten 
clinical hemostasis in various bleeding patient populations, 
including cardiovascular surgery, postpartum hemorrhage, 
and orthopedic surgery.45–47 European guidelines recommend 
the initiation of ﬁbrinogen replacement by ﬁbrinogen concen-
trate when the plasma ﬁbrinogen level falls below 1.5 g L1.11 
Holcomb et al have shown that ﬁbrinogen replacement via 
cryoprecipitate is often delayed and overlooked during an 
MTP;48 therefore, the use of ﬁbrinogen concentrate may be 
well justiﬁed in an emergency setting to augment clot ﬁrm-
ness and achieve better hemostasis. The cost of ﬁbrinogen 
concentrate is much greater than cryoprecipitate in some 
countries.
Tranexamic acid
Antiﬁbrinolytics, such as aminocaproic acid or tranexamic 
acid (TXA), inhibit the formation of plasmin; plasmin 
breaks down the ﬁbrin-based clot. Therefore, they are used 
to improve the durability and ﬁrmness of the clot in order 
to enhance clinical hemostasis. Antifibrinolytic agents 
have been shown to be clinically beneﬁcial in achieving 
hemostasis and reducing MT in exsanguinating trauma 
patients, especially after enhanced ﬁbrinolytic activity has 
been detected.49 Several published meta-analyses have 
demonstrated the efﬁcacy and safety of TXA for bleeding 
patients in various surgical settings.50–55 The largest 
prospective RCT utilizing antiﬁbrinolytics is the Clinical 
Randomization of an Antiﬁbrinolytic in Signiﬁcant Hemor-
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rhage 2 (CRASH-2) trial, a multicenter study that evaluated 
more than 10,000 trauma patients. The data analyses revealed 
that timely administration of TXA (within 3 hours of injury) 
was associated with a modest but highly signiﬁcant reduc-
tion in both overall and bleeding-related mortalities, but not 
in MOF or head injury. In addition, there was no signiﬁcant 
difference between the TXA and placebo groups in blood 
transfusion requirements or length of hospital stay.56,57 As 
the effect of TXA on isolated traumatic brain injury was not 
well characterized in the CRASH-2 study, the CRASH-3 
trial is now underway to determined optimal use of TXA in 
this patient population.58 The ﬁrst prospective RCT on the 
effectiveness of high-dose TXA (4 g loading dose with 1 g 
h1 over 6 hours) in women with postpartum hemorrhage was 
conducted in France. In the 144 subjects evaluated, TXA 
signiﬁcantly reduced blood loss and transfusions.59 Currently, 
the World Maternal Antiﬁbrinolytic Trial was established 
to examine the effect of TXA in women with postpartum 
hemorrhage on mortality and other adverse events.60
Evaluation of coagulopathy during 
MTP activation
Viscoelastic testing
Currently, central laboratory-based hemostatic evalua-
tions (eg, prothrombin time [PT], international normalized 
ratio [INR], activated partial thromboplastin time, ﬁbrinogen 
level/activity, and platelet count) are most commonly used 
in all clinical settings, including trauma. However, many of 
these tests are not designed for diagnosis of coagulopathy 
or to guide hemostatic therapy.61 In addition, they may not 
have adequate turn-around-time (TAT) to guide coagulation 
factor or platelet replacement during the fast pace of a MT. 
Thus, an accurate and rapid POC device to evaluate a patient’s 
pre- and post-transfusion clotting capacity would be a great 
asset to direct blood transfusion and the use of hemostatic 
agents. Currently, there are two POC assays to evaluate 
real-time global coagulation function using viscoelastic 
methodology: thrombelastography (TEG®) and rotational 
thromboelastometry (ROTEM®). Viscoelastic testing evalu-
ates the four main components of hemostasis: clot initiation, 
clotting ampliﬁcation, clot ﬁrmness, and the dynamics of 
ﬁbrinolysis (Figure 1). To date, there are more than 30 clini-
cal trials showing that viscoelastic testing can reduce blood 
transfusion and improve clinical outcomes in patients with 
surgery- and trauma-related massive hemorrhage. Tapia et al 
have shown that MT guided by TEG® is superior in resus-
citating patients with penetrating trauma when compared to 
standard MT practice.62 Notably, a recent prospective RCT 
showed that FIBTEM A5 (the clot ﬁrmness in a functional 
ﬁbrinogen test of ROTEM® at 5 minutes) is an independent 
predictor for greater than 2.5 L of blood loss during postpar-
tum hemorrhage.46 Similarly, Meyer et al demonstrated that 
ROTEM® clot ﬁrmness at 10 minutes was helpful in predict-
ing who would require MT in a trauma population.63 Thus, 
not only can viscoelastic testing provide real-time coagulation 
analysis, it also has the potential to predict large blood loss 
and may be a useful MTP prediction tool. In addition, it has 
the ability to guide early, targeted therapy and allows the 
monitoring and early treatment of hyperﬁbrinolysis. Many 
hospitals have incorporated immediate viscoelastic testing 
within an hour of admission and after each MTP cooler until 
bleeding is controlled surgically to enhance practice during 
trauma MTPs. With ROTEM®/TEG® monitoring, hemostatic 
therapy is guided using a combination of plasma (or PCCs 
in countries where they are available), platelets, ﬁbrinogen 
(ﬁbrinogen concentrate or cryoprecipitate), and antiﬁbrin-
olytic agents (TXA or aminocaproic acid). This approach 
is most effective when transfusion algorithms incorporating 
POC testing have been created and practitioners have been 
appropriately trained on the protocols. Additional studies 
evaluating the utilization of viscoelastic testing in non-trauma 
MTPs and the ideal location for testing POC/blood bank/
central laboratory would be worthwhile.
POC WB prothrombin time assay
Laboratory-based plasma PT and INR are simple tests 
designed to monitor warfarin effect, but they have been 
widely adopted to evaluate hemostasis and assess general 
bleeding risk. The use of PT/INR has been integrated into 
several predictive algorithms for MTP activation due to its 
simple procedure, low cost, and transfusion predictability;64–66 
however, its signiﬁcant delay in TAT (^30–60 minutes) 
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Figure 1 Parameters of ROTEM and TEG.
Abbreviations: MA, maximum amplitude; LY, clot lysis; TEG, thrombelastography; 
ROTEM, rotational thromboelastometry.
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makes it less practical to direct timely therapeutic decisions 
during patient resuscitation with blood products. With the 
availability of a POC PT/INR assay using WB, the results of 
the PT/INR can be rapidly available at the patient’s bedside 
during MT. Two observational studies have compared the 
performance of POC PT/INR assay against either plasma PT/
INR or TEG in the setting of trauma.67,68 The investigators in 
one study concluded that POC PT/INR assay has comparable 
accuracy to the laboratory-based PT/INR assay, and the abil-
ity to predict blood transfusion requirements.67 In addition, 
they reported a signiﬁcant reduction of TAT and laboratory 
costs (including reagents and labor). However, performance 
is speciﬁc to each individual POC device and larger studies 
examining various commonly used POC PT/INR devices in 
various clinical settings and types of coagulopathy will be 
required to gain full endorsement for this testing option.
Designing an optimal MTP
Predicting MTP utilization
As trauma patients requiring MT often die within 6 hours 
of medical resuscitation efforts,69,70 a reliable formula to 
predict MTP usage would be of great value. There are several 
published algorithms to predict the need for trauma-MTP 
in both civilian and military settings (Table 4).64–66,71–78 For 
example, Assessment of Blood Consumption scoring system 
developed by Cotton et al is a non-weighted scoring system 
that was validated at multiple Level I trauma centers. It is 
a simple system, relying on only a few rapidly obtainable 
clinical parameters, yet its performance was robust.76,79 Most 
recently, the shock index (SI), which is the ratio of heart rate 
to systolic blood pressure, was developed as a simple predic-
tor to evaluate trauma outcomes.80,81 Sohn et al have evaluated 
the use of SI in the setting of postpartum hemorrhage and 
found that SI can also independently predict the use of MTP 
in that setting.82 Other weighted scoring systems incorporat-
ing laboratory values, such as the Trauma-Associated Severe 
Hemorrhage and the Prince of Wales Hospital scores also 
appear to be reliable predictive tools for MTP utilization.83,84 
Furthermore, POC instrument-based predictive algorithms 
have gained a great deal of interest due to simplicity, faster 
TAT, and less inter-observer variability.75,77 There are sev-
eral published comparative studies to determine the ideal 
predictive system; however, the results vary due to different 
validation cohorts and study design biases. These systems 
have not been studied extensively in either the non-trauma 
MTP or pediatric MTP setting. A systematic comparison of 
these algorithms is needed to generate the best consensus 
practice to predict the need for MTP.
Logistical and safety considerations
Many MTPs begin with blood from a remote refrigerator in the 
emergency department or trauma bay. Often these refrigerators 
are stocked with Group O RBCs and occasionally TP in large 
trauma centers. Additional blood can be obtained from the 
blood bank in coolers. The amount and type of blood products 
per cooler varies depending on institutional preference and the 
blood bank inventory (see examples in Table 1).85–98 A pro-
longed MTP (more than 10–20 blood products) can quickly 
exhaust the supply of universal blood products, including 
Group O RBCs. Many blood banks use a rule of greater than 
10 units issued before switching to RhD positive (for RhD 
negative patients) or antigen untested RBCs for patients with 
atypical red cell alloantibodies, but occasionally if sufﬁcient 
RBC units are not available, the switch must occur earlier. 
During an MTP, time-consuming blood component processing, 
such as irradiation or cell washing, is not feasible.
Although MT can be life-saving, it carries inherent risk 
and harm that may occur when it is utilized inappropriately 
(Table 5). As blood products are needed emergently dur-
ing an MTP, routine pre-transfusion testing is bypassed. 
Uncrossmatched Group O RhD negative RBCs, Group AB 
Table 4 MT prediction algorithms
Algorithms Prediction parameters
Trauma-associated severe  
hemorrhage (TASH)
Hgb, base excess, systolic BP, HR, 
FAST (), male sex, pelvic and femur 
fractures
Prince of Wales  
Hospital (PWH)
Hgb, systolic BP, GCS, HR, FAST (), 
base deficit, pelvic fracture
Assessment of blood  
consumption (ABC)
Penetrating trauma, BP, HR, FAST ()
Trauma-induced Coagulopathy  
Clinical Score (TICCS)
Injury severity, BP, extent of injury
Automated software-derived  
prediction (Mackenzie et al77)
HR, SpO2, wave form analysis  
(pulse oximeter values)
Traumatic Bleeding Severity  
Score (TBSS)
Age, sex, systolic BP, FAST (),  
pelvic fracture, lactate
Leemann et al75 ROTEM (A5, A10, Maximum Clot 
Firmness)
Olaussen et al81 Shock Index (HR, systolic BP)
Barbosa et al78 GCS, pH, HR, age, Injury Severity 
Score, 6-hour RBC transfusion 
requirement
Huang et al64 Pre-operative INR
Hsu et al65 INR, base deficit, hemoperitoneum at 
laparotomy
Callcut et al66 INR, systolic BP, Hgb, base deficit, 
FAST (), HR, penetrating trauma
Abbreviations: Hgb, hemoglobin; BP, blood pressure; HR, heart rate; FAST, 
Focused Assessment with Sonography in Trauma; GCS, Glascow Coma Scale; SpO2, 
peripheral blood oxygen saturation; INR, international normalized ratio.
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or low titer Group A plasma, and Group AB or A platelets 
are conventionally used. These blood products may result 
in various adverse transfusion events, including hemo-
lysis, alloimmunization, hypothermia, citrate toxicity, and 
 hyperkalemia. The switch from Group O RhD negative RBCs 
to the patient’s speciﬁc blood type should occur as soon as 
possible after the patient’s blood type has been conﬁrmed 
on two independent specimens.
Timely MTP activation and deactivation
MT is a resource-intensive process. As exsanguination-
associated death usually happens during the ﬁrst few hours 
of admission, this resuscitative effort needs to occur within 
minutes. For many trauma centers, the time to issue the ﬁrst 
MTP cooler is usually within 5–10 minutes from protocol 
activation. Given the need for rapid TAT and large amounts 
of different blood products, the blood bank often requires 
a dedicated team to coordinate blood preparation for the 
 duration of MTP activation. Predictably, the rapid mobi-
lization of large amounts of blood products in response to 
highly unpredictable clinical needs often results in inefﬁcient 
use and blood product wastage. To ensure that an MTP is 
legitimately activated and to reduce potential unnecessary 
blood transfusion, transfusion medicine specialists are often 
consulted prior to commencing with MTP blood preparation, 
especially for non-trauma cases. In parallel, the clinical physi-
cians should be educated on the appropriate use of MTPs. At 
the bedside, the clinician who activates the MTP should serve 
as the liaison to inform the blood bank about the need for 
continuing transfusion support or deactivation of the MTP. 
Timely deactivation of MTPs not only reduces wastage, but 
also may prevent unnecessary adverse events associated with 
MTP. A formal retrospective process involving the blood 
bank and the clinical teams to evaluate the efﬁciency and 
performance of each MTP and the associated outcomes can 
be beneﬁcial to continuously improve the MTP.
Appropriate product ratios during MT
Without the universal availability of POC testing, an optimized 
transfusion strategy with appropriate blood component selec-
tion is critical. Several published retrospective studies have 
shown that a higher plasma to RBC ratio in MT is associated 
with better survival in patients with traumatic injuries.99 Since 
2007, there has been a rather accelerated shift in MT practice 
to utilize a higher plasma:platelet:RBC ratio.100,101 However, the 
retrospective studies are thought to be ﬂawed due to survival bias 
(patients who survive longer are more likely to receive plasma). 
Holcomb et al conducted a prospective observational study on 
the effect of a higher plasma:RBC ratio on in-hospital mortality. 
Over 900 eligible trauma patients receiving more than three 
Table 6 Summary of findings from PROMMTT and PROPPR studies
PROMMTT102 PROPPR103
Year 2013 2015
Source JAMA surgery JAMA
Study design Prospective observational Randomized control trial
Intervention Plasma:RBCs (1:1) Plasma:platelets:RBCs (1:1:1); n338
Control Plasma:RBCs (1:2) Plasma:platelets:RBCs (1:1:2); n342
Cohort size (n) 905 680
Generalizability Multicenter study Multicenter study
Follow-up 24-hour and 30-day 24-hour and 30-day
Primary endpoint In-hospital mortality 24-hour and 30-day mortality
Outcomes Higher plasma:RBC ratio decreases 6-hour mortality  
in patients who received 3 blood products; however,  
no association found after 24 hours of survival
No significant difference in 24-hour and 30-day mortality  
or complications. 1:1:1 group achieved earlier hemostasis 
and had less mortality due to exsanguinations in 24 hours
Abbreviations: PROMMTT, Prospective Observational Multicenter Major Trauma Transfusion; PROPPR, Pragmatic, Randomized Optimal Platelet and Plasma Ratios.
Table 5 Adverse complications associated with massive transfusion
Acute Delayed
TRALI Hemolysis
TACO TRIM
Citrate toxicity/hypocalcemia Transfusion-associated GvHD
Hypothermia Microchimerism
Allergic reaction Transfusion-transmitted infection
Hyperkalemia Posttransfusion purpura
Hemodilution (pediatric)
Dilutional coagulopathy/
thrombocytopenia
Febrile non-hemolytic transfusion 
reaction
Electrolyte and acid–base imbalance
Infection
Multiorgan failure
Systemic inflammatory response 
syndrome
Abbreviations: TRALI, transfusion-related acute lung injury; TACO, transfusion-
associated fluid overload; TRIM, transfusion-related immunomodulation; GvHD, 
graft versus host disease.
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RBCs unit were analyzed and found that less than 1 plasma for 
every 2 RBC products is associated with a  three- to four-fold 
higher death risk within 6 hours of admission.102 However, the 
transfused plasma:RBC ratio signiﬁcantly varied within the 
analyzed cohort. To control for this potentially clinically sig-
niﬁcant variable, the Pragmatic, Randomized Optimal Platelet 
and Plasma Ratios study was conducted to examine the effect 
of 1:1:1 versus 1:1:2 plasma:platelet:RBC ratio on 24-hour and 
30-day all-cause mortality.103 The study showed that while there 
was no difference in the examined all-cause mortality, there was 
earlier hemostasis, lower transfusion requirements, and less 
death due to exsanguination at 24 hours in the 1:1:1 ratio group 
(Table 6). While there are still study limitations and biases due to 
the complex nature of conducting a multicenter RCT in a trauma 
setting, the Pragmatic, Randomized Optimal Platelet and Plasma 
Ratios study concluded that the higher plasma:platelet:RBC 
ratio appeared to be effective in reducing mortality. A higher 
fibrinogen-to-RBC ratio is also associated with improved 
survival during MT.104 More controlled investigations are still 
required to establish optimal blood product ratios.
Summary
In conclusion, the best practice for MT includes an established 
institutional deﬁnition of MT, an accurate method for predict-
ing which patients will require MT so therapy can be promptly 
initiated and over-utilization can be avoided, and ﬁnally, an 
established MT protocol with a clear plan for activation and 
use of appropriate blood products to maintain hemostasis.105 
This can be achieved either by goal-directed therapy with POC 
testing or, when point-of-care testing is not available, ﬁxed ratios 
of blood products approximating a ratio of 1:1:1, with early ini-
tiation of ﬁbrinogen replacement. Adherence to the established 
protocol is critical to extract the full clinical beneﬁt of an MTP 
for treating either trauma or non-trauma patients.
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